|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Novolog
|
|
gptkbp:activities
|
rapid-acting insulin
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:Novo_Log_Mix_70/30
Novo Rapid
|
|
gptkbp:clinical_trial
|
Phase III
mealtime insulin
Efficacy in Type 1 Diabetes
Efficacy in Type 2 Diabetes
|
|
gptkbp:contraindication
|
severe hypoglycemia
hypersensitivity to insulin aspart
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:duration
|
3 to 5 hours
|
|
gptkbp:education
|
proper injection technique
recognize hypoglycemia symptoms
monitor blood glucose
dietary considerations
exercise management
|
|
gptkbp:form
|
injection
|
|
gptkbp:highest_point
|
1 to 3 hours
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novo Log
|
|
gptkbp:ingredients
|
gptkb:insulin_aspart
|
|
gptkbp:interacts_with
|
gptkb:beer
gptkb:ACE_inhibitors
beta-blockers
thiazolidinediones
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_available_in
|
vials
pre-filled pens
|
|
gptkbp:is_used_for
|
diabetes management
|
|
gptkbp:manager
|
subcutaneous
|
|
gptkbp:manufacturer
|
gptkb:Novo_Nordisk
|
|
gptkbp:marketed_as
|
gptkb:2000
|
|
gptkbp:packaging
|
multi-dose vials
single-use pens
|
|
gptkbp:pharmacokinetics
|
fast absorption
short duration of action
lowering blood glucose levels
|
|
gptkbp:population
|
gptkb:Person
adults
|
|
gptkbp:premiered_on
|
10 to 20 minutes
|
|
gptkbp:previous_name
|
gptkb:insulin_aspart
|
|
gptkbp:provides_information_on
|
EASD guidelines
ADA Standards of Medical Care
|
|
gptkbp:safety_features
|
Long-term safety of insulin aspart
|
|
gptkbp:side_effect
|
weight gain
injection site reactions
hypoglycemia
|
|
gptkbp:storage
|
refrigerated
|